Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: An evidence-based analysis

American Journal of Transplantation

Volumn 6, Issue 11, 2006, Pages 2644-2650

  Lesurtel, M ^a   Mullhaupt B ^a   Pestalozzi, B C ^a   Pfammatter, T ^a   Clavien, P A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chemoembolization; Evidence based medicine; Hepatocellular carcinoma; Liver transplantation; Neoadjuvant treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IODINATED POPPYSEED OIL; MITOXANTRONE;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; META ANALYSIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PATIENT DROPOUTS; PATIENT SELECTION; WAITING LISTS;

EID: 33749995718     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01509.x     Document Type: Review

References (36)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
3. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401.
4. Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990; 66: 1897-1903.
5. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: Review of the randomised clinical trials. Lancet Oncol 2002; 3: 593-603.
6. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
7. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-1739.
8. Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Metaanalysis of randomized controlled trials. Radiology 2002; 224: 47-54.
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442.
10. Iwatsuki S, Gordon RD, Shaw BW, Jr., Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg 1985; 202: 401-407.
11. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
12. Yokoyama I, Todo S, Iwatsuki S, Starzl TE. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology 1990; 37: 188-193.
13. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110: 726-734. discussion 734-5.
14. Majno PE, Adam R, Bismuth H et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701. discussion 701-3.
15. Oldhafer KJ, Chavan A, Fruhauf NR et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: Marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29: 953-959.
16. Harnois DM, Steers J, Andrews JC et al. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg 1999; 5: 192-199.
17. Roayaie S, Frischer JS, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533-539.
18. Graziadei IW, Sandmueller H, Waldenberger P et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-563.
19. Maddala YK, Stadheim L, Andrews JC et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization. Liver Transpl 2004; 10: 449-455.
20. Hayashi PH, Ludkowski M, Forman LM et al. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 2004; 4: 782-787.
21. Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-775.
22. Perez Saborido B, Meneu JC, Moreno E, Garcia I, Moreno A, Fundora Y. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg 2005; 190: 383-387.
23. Sackett DL, Straus SH, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine. How to Practice and Teach EBM. 2nd Ed. Edinburg: Churchill Livingstone, 2000.
24. http://www.cbem.net 2001.
25. Konno T, Maeda H, Iwai K et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053-1065.
26. Kanematsu T, Furuta T, Takenaka K et al. A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989; 10: 98-102.
27. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989; 64: 1586-1594.
28. Raoul JL, Heresbach D, Bretagne JF et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992; 70: 585-590.
29. Cherqui D, Piedbois P, Pierga JY et al. Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer 1994; 73: 2721-2726.
30. Spreafico C, Marchiano A, Regalia E et al. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology 1994; 192: 687-690.
31. Venook AP, Ferrell LD, Roberts JP et al. Liver transplantation for hepatocellular carcinoma: Results with preoperative chemoembolization. Liver Transpl Surg 1995; 1: 242-248.
32. International Union Against Cancer (UICC). In: Sobin LH, Wittekind CH, eds. TNM Classification of Malignant Tumors. 5th Ed. New York: Wiley-Liss, 1997:74-77.
33. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-1440.
34. Richard HM, 3rd, Silberzweig JE, Mitty HA, Lou WY, Ahn J, Cooper JM. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology 2000; 214: 775-779.
35. Yao FY, Bass NM, Nikolai B et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl 2003; 9: 684-692.
36. Sharma P, Balan V, Hernandez JL et al. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl 2004; 10: 36-41.